Skip to main content
Quest Diagnostics

Establishing Measurement Uncertainty for Tumor Markers: Impact of Analytical Variation in Quality Control Material vs Patient Serum Matrix

ADLM 2026

Association for Diagnostics and Laboratory Medicine

Anaheim, CA, June 26-30, 2026,

Poster presentation: Establishing Measurement Uncertainty for Tumor Markers: Impact of Analytical Variation in Quality Control Material vs Patient Serum Matrix

Authors: Vivek Kumar, Alice Gallegos

Medical Specialty: Oncology

Related content

Publication
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Audio Podcast
Exploring Digital Pathology and Artificial Intelligence

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.